Itching drug trial for dialysis patients halted early

NCT ID NCT04393675

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a skin-applied drug called LT5001 for severe itching in people on hemodialysis. The trial was stopped early after enrolling only 18 participants. The main goal was to check safety and how the drug behaves in the body, not to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LT5001 (a drug applied to the skin)

What this could lead to

If it had worked, this could have pointed toward a new treatment for severe itching in dialysis patients.

What could go wrong

The trial was terminated early with only 18 participants, so results are very limited. It is unclear if LT5001 is safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • China Medical University Hospital

    Taichung, Taiwan